Important note: Information in this article was accurate in 2005. The state of the art may have changed since the publication date.
|
|
United Press International - September 27, 2005
A cost-effectiveness analysis indicates performing genotype resistance testing at initial HIV diagnosis -- prior to treatment -- can effectively guide a physician's choice of treatment regimen and increase a patient's quality-adjusted life expectancy.
"For the approximately 90 percent of patients with no resistance, the testing provides no benefit," said lead author Dr. Paul Sax of Brigham and Women's Hospital. "However, if certain types of resistance are present, our study projects a substantial increase in survival" of more than 14 months, compared with no resistance testing.
It's estimated that in the United States and Europe, the average resistance rate in treatment-naive patients is between 8 percent and 10 percent, although baseline resistance may be as high as 16 percent in gay men.
Using a model with a resistance rate of just more than 8 percent, the analysis estimated a cost of $23,900 per quality-adjusted life year gained.
The research appears in the Nov. 1 online issue of Clinical Infectious Diseases.
050927
UP050911
Copyright © 2005 - United Press International. All rights reserved. Reproduced with permission. Reproduction of this article (other than one copy for personal reference) must be cleared through United Press International, Permissions Desk, 1510 H St. N.W. Washington DC 2005. Main Phone Switchboard: 202-898-8000 FAX: 202-898-8057 or 202-898-8147 Email: info@upi.com.
AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Elton John AIDS Foundation UK, the National Library of Medicine, AIDS Walk of Orange County, and donations from users like you.
Always watch for outdated information. This article first appeared in 2005. This material is designed to support, not replace, the relationship that exists between you and your doctor.
AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.
Copyright ©1980, 2005. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .